logo
Workers at community-owned grocery store in the South Wedge move to unionize

Workers at community-owned grocery store in the South Wedge move to unionize

Yahoo13-03-2025

Workers at Abundance Co-op, a community-owned grocery store in Rochester's South Wedge neighborhood, announced this week that they are unionizing—marking the first union effort in the co-op's history.
Abundance Co-op specializes in local, organic, and sustainable products, serving the community with a focus on ethical and environmentally friendly goods.
At Abundance Co-op, everyday consumers own shares in the business, its products are sourced from local growers, and shoppers prioritize natural and organic foods.
'We appreciate our work at Abundance, and we believe that with a union, we can build the structures we need to make the store better,' said Ben Fetterolf, a produce team member. 'We want to make the improvements we know will help realize the store's potential as a benefit to the community and workers.'
Some of the proposed improvements include better communication between workers and management, stronger advocacy for internal concerns, and protections against unfair disciplinary action.
Since going public with their campaign, workers have contacted Abundance Co-op management, hoping they will agree to a fair election process and uphold the co-op's democratic values: self-help, self-respect, democracy, equality, equity, and solidarity.
'Having a union at a consumer co-op is just common sense,' said Bailey Stevens, a front-end team member. 'The union is to the workers what the shareholders are to the customers. Everyone with a stake in the co-op deserves representation.'
Workers filed for a union election on March 11.
Abundance Co-op management has yet to respond to the union. When asked by D&C reporters, they declined to comment on the workers' unionization efforts.
Bailey Stevens said the new union's effort is about keeping its culture and "keeping the ability to serve and put our community and customers first."
—As a Rochester native, Justice Marbury entered the world of journalism to create work where voices like hers were heard—the voices of minority communities. Marbury covers small businesses, neighborhood concerns, and the interesting people who live in Rochester's 19th Ward. As the 19th Ward reporter, she has helped implement community outreach ideas by asking what people in various communities want to read about themselves in addition to regular news. Contact her on Instagram @justice_marbury and by email at jmarbury@gannett.com.
This article originally appeared on Rochester Democrat and Chronicle: Abundance Co-op workers in Rochester NY move to unionize

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FDA approves YolTech's YOLT-101 for familial hypercholesterolemia
FDA approves YolTech's YOLT-101 for familial hypercholesterolemia

Yahoo

time28 minutes ago

  • Yahoo

FDA approves YolTech's YOLT-101 for familial hypercholesterolemia

YolTech Therapeutics has received the US Food and Drug Administration (FDA) approval for its investigational new drug (IND) application for YOLT-101 to treat heterozygous familial hypercholesterolemia (HeFH). YOLT-101 is an in vivo base editing therapy designed to target proprotein convertase subtilisin/kexin type 9 (PCSK9). Its innovative approach lies in its potential to durably reduce blood low-density lipoprotein cholesterol (LDL-C) levels through a single-dose treatment. The technology behind YOLT-101 incorporates YolTech's adenine base editor, known as hpABE5, which consists of nCas and a new deaminase evolved from Hafnia paralvei. To deliver this therapeutic agent, the company employs an advanced lipid nanoparticle (LNP) delivery system. hpABE5 can perform precise A•T to G•C base conversions without inducing DNA double-strand breaks, thus minimising risks associated with chromosomal abnormalities and off-target effects. YolTech Therapeutics co-founder and CEO Yuxuan Wu stated: 'The FDA IND clearance marks a significant milestone for YolTech. In vivo gene editing represents a new generation of therapeutics — offering one-time, durable solutions for chronic and genetic diseases. 'We are committed to advancing breakthrough gene editing solutions that offer transformative benefits for patients living with severe genetic and cardiovascular diseases.' Currently under evaluation in an ongoing investigator-initiated trial (IIT), YOLT-101 has shown promising results with a favourable safety profile and substantial LDL-C–lowering effects. Familial hypercholesterolemia is a genetic disorder stemming from mutations affecting LDL metabolism-related genes such as LDLR, Apolipoprotein B (APOB) and PCSK9. Individuals suffering from FH typically experience elevated LDL-C levels, which contribute to a heightened risk of developing early-onset atherosclerotic cardiovascular diseases. "FDA approves YolTech's YOLT-101 for familial hypercholesterolemia" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio

GFL Is Said to Consider Sale of Stake in C$5 Billion Infra Arm
GFL Is Said to Consider Sale of Stake in C$5 Billion Infra Arm

Bloomberg

time41 minutes ago

  • Bloomberg

GFL Is Said to Consider Sale of Stake in C$5 Billion Infra Arm

GFL Environmental Inc. is considering the sale of a stake in its infrastructure arm, people with knowledge of the matter said, in what could be one of Canada's largest infrastructure deals this year. The company is seeking a valuation of as much as C$5 billion ($3.7 billion) including debt for the affiliate, known as Green Infrastructure Partners Inc., the people said. The stake sale is attracting initial interest from potential investors including General Atlantic, Energy Capital Partners and Neuberger Berman, the people said.

Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial
Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial

Yahoo

timean hour ago

  • Yahoo

Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial

PolyPid Ltd. (NASDAQ:PYPD) on Monday announced topline results from its pivotal SHIELD II Phase 3 trial of D-PLEX100 to prevent surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. The SHIELD II trial is designed to assess the efficacy and safety of D-PLEX100 administered concomitantly with the standard of care (SoC), which includes prophylactic systemic antibiotics, compared to the SoC alone arm in the prevention of post-abdominal-surgery incisional infection in patients undergoing abdominal colorectal surgeries with large incisions. The trial's primary endpoint is measured by the proportion of subjects with a surgical site infection or mortality for any reason within 30 days post-surgery. FDA Pushes Pause On Axsome Fibromyalgia Drug, New Trial Required Patient safety will be monitored for an additional 30 days. The trial will enroll patients in centers in the United States, Europe, and Israel. D-PLEX100, PolyPid's lead product candidate, is designed to provide local, prolonged, and controlled antibacterial activity directly at the surgical site to prevent SSIs. Following the administration of D-PLEX100 into the surgical site, the PLEX (Polymer-Lipid Encapsulation matriX) technology pairs with Active Pharmaceutical Ingredients, enabling a prolonged and continuous release of the broad-spectrum antibiotic doxycycline, resulting in a high local concentration of the drug for 30 days for the prevention of SSIs, with additional potential to prevent SSIs caused by antibiotic-resistant bacteria at the surgical site. The trial met the primary efficacy endpoint, with a significantly lower proportion of primary endpoint events among patients who received D-PLEX100 plus SoC (n=405; 10.9%), compared to SoC alone (n=393; 18.1%), representing a 38% reduction (p<0.005). SHIELD II included three key secondary endpoints: The first key secondary endpoint was met, with a 58% reduction in deep and superficial SSI rates among patients who received D-PLEX100 plus SoC (3.8%) compared to those who received SoC alone (9.5%) (p<0.005). The second key secondary endpoint showed statistical significance in favor of D-PLEX100 plus SoC over SoC alone (p<0.005). The third key secondary endpoint was met with a 62% reduction of patients with an ASEPSIS1 score >20 in the D-PLEX100 plus SoC arm compared to the SoC alone arm (p<0.05). The ASEPSIS score is a clinical tool used to assess surgical wound infections objectively. The independent Data Safety Monitoring Board raised no safety concerns in SHIELD II. The company expects to submit a New Drug Application to the U.S. Food and Drug Administration in early 2026, with a Marketing Authorization Application in the E.U. to follow shortly thereafter. Price Action: PYPD stock is trading higher by 12% to $3.66 at last check Monday. Read Next:Photo by ittawit21 via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? This article Nano-Cap PolyPid's Lead Drug Candidate Cuts Surgical Infection Risk by 38% In Phase 3 Trial originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store